Eli Lilly and Company (LLY) failed to extend gains with the stock declining -0.26% or $-0.21 to close the day at $80.04 on light trading volume of 3.63M shares, compared to its three month average trading volume of 6.13M. The Indianapolis Indiana 46285 based company has been outperforming the drug manufacturers – major group over the past 52 weeks, with the stock gaining 11.84%, compared to the industry which has advanced 13.14% over the same period. With RSI of 72.6, the stock should still continue to rise and get closer to its one year target estimate of $86.35, making it a hold for now.
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; and chronic allergic dermatitis and kidney diseases in cats. It has a clinical collaboration agreement with Athenex, Inc.; and a research agreement with AstraZeneca for the development of clinical candidate MEDI1814 as a disease-modifying treatment for Alzheimer’s disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Synchrony Financial (SYF) retreated with the stock falling -1.15% or $-0.43 to close at $36.85 on light trading volume of 3.62M compared its three months average trading volume of 6.13M. The Stamford Connecticut 06902 based company operating under the Credit Services industry has been trending up for the last 52 weeks, with the shares price now 40.22% up for the period and up by 1.97% so far this year. With price target of $42.91 and a 60.55% rebound from 52-week low, Synchrony Financial has plenty of upside potential, making it a hold with a view buy.
Synchrony Financial operates as a consumer financial services company in the United States. The company offers private label credit cards, dual cards, and small and medium-sized business credit products; and promotional financing for consumer purchases, such as private label credit cards and installment loans. It also provides promotional financing to consumers for elective healthcare procedures or services, such as dental, veterinary, cosmetic, vision, and audiology; debt cancellation products; and deposit products, including certificates of deposit, individual retirement, money market, and savings accounts, as well as accepts deposits through third-party securities brokerage firms. The company offers its credit products through programs established with a group of national and regional retailers, local merchants, manufacturers, buying groups, industry associations, and healthcare service providers; and deposit products through multiple channels, including online, print, and radio advertising. Synchrony Financial was incorporated in 2003 and is headquartered in Stamford, Connecticut. Synchrony Financial operates independently of GE Consumer Finance, Inc. as of November 17, 2015.
Enterprise Products Partners L.P. (EPD) failed to extend gains with the stock declining -0.24% or $-0.07 to close the day at $28.87 on lower than average trading volume of 3.6M shares, compared to its three month average trading volume of 5.2M. The Houston Texas 77002 based company has been outperforming the independent oil & gas companies by 12.7969% for last three months and its recent gains have pushed the stock slightly up 6.77% YTD, versus the independent oil & gas industry which is down -3.29% for the same period. The RSI of 62.23 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
Enterprise Products Partners L.P., a master limited partnership, provides midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals, and refined products. The company operates through NGL Pipelines & Services, Crude Oil Pipelines & Services, Natural Gas Pipelines & Services, and Petrochemical & Refined Products Services segments. The NGL Pipelines & Services segment provides natural gas processing and related NGL marketing services, as well as NGL export docks and related services. It operates approximately 19,500 miles of NGL pipelines; NGL and related product storage facilities; 15 NGL fractionators; and a liquefied petroleum gas export terminal and NGL import facility. The Crude Oil Pipelines & Services segment operates approximately 5,400 miles of crude oil pipelines and related operations; and crude oil storage and marine terminals located in Oklahoma and Texas, as well as a fleet of 478 tractor-trailer tank trucks used to transport crude oil. It also engages in crude oil marketing activities. The Natural Gas Pipelines & Services segment operates approximately 19,100 miles of natural gas pipeline systems to gather and transport natural gas in Colorado, Louisiana, New Mexico, Texas, and Wyoming. It leases underground salt dome natural gas storage facilities in Texas and Louisiana; owns an underground salt dome storage cavern in Texas; and markets natural gas. The Petrochemical & Refined Products Services segment operates propylene fractionation and related operations, including 674 miles of pipelines; butane isomerization complex, associated deisobutanizer units, and related pipeline assets; and octane enhancement and high purity isobutylene production facilities. It also operates refined products pipelines of approximately 4,200 miles; and terminals, as well as provides refined products marketing and marine transportation services. The company was founded in 1968 and is based in Houston, Texas.